Royalty Rates for Pharmaceuticals & Biotechnology features more real-deal royalty rates, license fees, and milestone payment benchmarks than any other publication.
The ninth edition of Royalty Rates for Pharmaceuticals & Biotechnology contains hundreds of royalty rates and other financial compensation benchmarks that can be used to optimize the pricing of biotechnology and pharmaceutical innovations. You'll find updated and expanded information from past editions as well as an increased number of reported license agreements.
This new edition and the transaction details have been collected from well-established sources over a period of 22 years of research. Royalty Rates for Pharmaceuticals & Biotechnology provides real-deal information for hundreds of transactions, including the technology licensed, royalty rates, license fees, and milestone payments. And it goes well beyond the rates to provide context for each deal analyzed.
This unique resource is organized into two useful sections:
The first section covers the theory associated with deriving royalty rates.
An overview of intellectual property value is included along with seven methods that can be employed to derive royalty rates: Simple Rules of Thumb, Industry Guidelines, Discounted Cash Flow Analysis, Risk-Adjusted Net Present Value Analysis, Infringement Damages Analysis, Comparable License Transactions, Investment Rate of Return Analysis, and the Relief-From-Royalty Method.
The second section of this one-of-a-kind report presents detailed financial information from real-world transactions.
You'll find information on the parties involved in the transactions along with a description of the technology exchanged and all financial details that could be discovered. This publication is designed to provide accurate and authoritative information about the subject matter covered.
Key Topics Covered:
1,2-diphenylethanes, 1,3-diphenylpropanes and benzyl tetralins
Abuse Deterrent
Actimmune - interferon gamma-1b
Adult Growth Hormone Deficiency
Agriculture
Alcohol Dependency Treatment
Aldurazyme - recombinant form of the human enzyme alpha-L-iduronidase
Alpha Interferon - Natural
Alzheimer's Treatment
Alzheimer's Diagnostic Test
Anemia
Anesthetic
Animal Health Products
Antibiotic
Antibodies
Antifungal
Antifungal Agent - Amphotericin B
Anti-hypertension Therapy
Arginine Products
Arthritis - Rheumatoid - Drug Humira
Asthma Drug - Oral Administration
Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder Therapy
Autoimmune Disease Therapy
Automated Cell Processing Instrument
Automated Process Research
Bacterial Infections
BetaKine (TGF-beta-2)
Bicifadine
Biochemical Technology Portfolio
Blood
BPI - Human Protein
Cancer
Cancer Diagnostics
Cancer- Histone Deacetylase (HDAC) Inhibitors
Cancer LukemiaTreatment
Cancer Research Technology
Cancer Therapy
Cancer Treatment
Cannabinoid Receptor Meditating Compounds
Cardiorenal Disease Therapies
Cardiovascular
Cartilage Regenerative Technology
Catheter Technology
cdkl Assay
Cell Adhesion Technology - LEC-CAM
Cell Cultures
Chimeric IgG1 antibodies
Cholesterol High LDL Treatment
Cholesterol Treatment
Chromosome Analysis Technology
Chronic Obstructive Pulmonary Disease Therapy
Cochleates, Liposomes and Proteoliposomes
Cold Remedy
Collagenase Ointment
Consensus Interferon
Contraceptive
Contrast Agent - Intravenous
COPD Treatment
Coronary Drug-eluting Stent
Cough Medicine
Crohn's Disease Therapy
Cyclin Dependent Kinasc Assay Test Kit
Cypress Stem Cells
Cystic Fibrosis Treatment
Cytomegalovirus Intravenous Treatment
Deferrum deferiprone
Dermatology
Diabetes
Diagnostic Alliance
Diagnostic Imagining Using Ligands
Dietary Supplement - Botanical
Diltiazem Heart Drug
DNA - PK
DNA Binding Invention
DNA Nanocircles
DNA Synthesis
Drug Delivery
EGF Fusion Protein
Eli Lilly & Co. Experiences Compulsory License Royalty Rates
Enoxaparin
Environmental Test Kit
Enzyme Inhibitors
Epilepsy Treatment - ADCI
EPO, Hepatitis B and IL-2
Erectial Dsyfuction Therapy - VitarosT
Erythronmycin Antibiotic
Estrogen Replacement Therapy
Fertility Treatment
Fibrotic Disease Therapy - Pirfenidone
Financing Research
Fusion Inihibitors for HIV
Gastrointestinal Infection
Gastroretentive Drug Delivery Devices for Oral Intake
Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased...
Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora...
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") for violations of 10(b) and 20(a) of the Securities...
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...